Starting treatment [1, 8] Consider treating immediately if BP in clinic is ≥180/110 mm Hg; otherwise, consider after results of ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM), blood tests and cardiovascular risk assessment are available.
Diagnose hypertension if the average of ABPM or HBPM readings is ≥135/85 mm Hg, (ignore first-day readings and average the rest -see separate Hypertension article).
Stage 1 hypertension -clinic readings ≥140/90 mm Hg and ABPM/HBPM ≥135/85 mm Hg. Stage 2 hypertension -clinic readings ≥160/100 mm Hg and ABPM/HBPM ≥150/95 mm Hg.
Antihypertensive treatment should be commenced in people aged under 80 years with stage 1 hypertension plus signs of end-organ damage (known cardiovascular or renal disease), or with diabetes mellitus or a 10-year cardiovascular disease (CVD) risk ≥20%. Treatment in mild hypertension without target-organ damage or cardiovascular risk remains contentious [9] .
Treatment should be started in all patients (any age) with stage 2 hypertension. Treat isolated systolic hypertension in the same way.
Initial antihypertensive choices
If the patient is young (≤55 years) and non-black, start with: (A) angiotensin-converting enzyme (ACE) inhibitor or low-cost angiotensin-II receptor antagonist (AIIRA) -also called an angiotensin receptor blocker (ARB).
A beta-blocker may be appropriate in younger adults if an ACE inhibitor is not tolerated, in women who may become pregnant or if there is evidence of increased sympathetic drive. Beta-blockers were the B in the previous ABCD hypertension advice but are no longer preferred treatment, as evidence suggests they are inferior to other agents in terms of outcome [10] .
If the patient is aged >55 years or a black person of African or Caribbean family origin, use: (C) calcium-channel blocker (CCB). (D) thiazide-like diuretic if CCB not suitable. Chlortalidone (12.5-25.0 mg once daily) or indapamide (1.5 mg modifiedrelease once daily or 2.5 mg once daily) are specifically recommended choices.
Step 2 choices (A+C) ACE inhibitor or AIIRA with CCB. Use an ACE inhibitor/AIIRA and a thiazide-like diuretic (D) if CCB is not tolerated (or if there is any evidence of heart failure). If initially started on a beta-blocker, add a CCB rather than a thiazide-like diuretic second-line (reduce diabetic risk). Consider an AIIRA rather than an ACE inhibitor with a CCB in black people of African or Caribbean origin.
Step 3 choices (A+C+D) ACE inhibitor or AIIRA and a CCB and a thiazide-like diuretic (chlortalidone or indapamide).
Step 4 choices
Consider a fourth agent or referral for specialist advice.
(A+C+D) ACE inhibitor or AIIRA and a CCB and a thiazide-like diuretic plus a further diuretic (higher-dose thiazide-like diuretic or spironolactone, depending on potassium). Monitor renal function and electrolytes. If the higher-dose diuretic is not tolerated, consider an alpha-blocker or a beta-blocker, or seek expert advice.
The combination of an ACE inhibitor with an AIIRA is not recommended for the treatment of hypertension.
The PATHWAY-2 trial, published in 2015, suggested that spironolactone is the most effective fourth-line agent for resistant hypertension [11] . A drug safety update from the Medicines and Healthcare products Regulatory Agency (MHRA) in 2016 warns of the risk of hyperkalaemia when an ACE inhibitor or AIIRA is combined with spironolactone [12] . Routine use of this combination is not recommended but where it is, the lowest possible dose should be used and electrolytes monitored closely.
Treatment targets
Current targets [1, 8] People 
Latest research
Recent research tends to suggest more aggressive treatment targets may be appropriate in future.
The Systolic Blood Pressure Intervention Trial (SPRINT) study, published in 2015, showed that a target of below 120 mm Hg rather than below 140 mm Hg for systolic blood pressure led to significant reduction in deaths and cardiovascular events, albeit with an increased incidence of adverse events [13] .
A systematic review and meta-analysis published in the Lancet in 2016 (but not including the SPRINT study) also showed a significant reduction in cardiovascular events with more intensive treatment [14] .
Benefits of treating hypertension
Research continues to demonstrate the significant benefits of lowering high blood pressure. A large 2016 systematic review and meta-analysis showed [15] :
Each 10 mm Hg reduction of systolic blood pressure was associated with an overall relative reduction in risk of major cardiovascular event of 20%, and a reduction of mortality of 13%. There was no evidence of a level of BP reduction below which there is not further benefit. There was no evidence of increased risk at lower BP levels. CCBs were most effective in reducing the risk of stroke, whereas diuretics were most effective in reducing the risk of heart failure.
Self-monitoring may result in better BP control [16] .
Specialist referral
Refer if hypertension is difficult to control in spite of the steps above [17] .
Consider seeking specialist evaluation of patients aged <40 years who appear to have stage 1 hypertension without target organ damage or diabetes, either for exclusion of secondary causes of hypertension or a more detailed assessment of cardiovascular risk, as standard assessments can underestimate the lifetime risk in these people [1, 8] .
Hypertension in the context of multimorbidity
Multimorbidity is increasingly the norm. One UK-based study found that two thirds of people with hypertension have a co-morbidity [18] . Those with multimorbidity tend to be excluded from trials, making it difficult to determine optimum management. Management needs to be tailored to the individual, and NICE has developed guidelines to aid in the assessment and management of those with multimorbidity [19] .
A 2016 paper in the British Medical Journal (BMJ) collates advice from the disease-specific NICE guidelines to make recommendations about choices in these conditions, which may represent different choices from those in the hypertension NICE guidelines [20] :
Chronic heart failure: people would normally already be on A and a beta-blocker. Add D, and if still not controlled, refer for specialist advice to consider spironolactone. Diabetes: A is first-line in type 1 and type 2. Add D as second-line and C as third-line. For type 2 diabetes, if of black African or Caribbean origin, use A + D or A + C first-line. Atrial fibrillation: if rate control is needed, add a beta-blocker (but not sotalol) or a rate-limiting CCB such as diltiazem. If on amlodipine, change to a rate-limiting CCB such as diltiazem. Chronic kidney disease: treatment depends on whether there is diabetes or not and on the albumin:creatinine ratio (ACR). A would normally be the first choice. 
